- Home
- ASTI vs GRI Comparison
ASTI vs GRI Comparison
Compare ASTI & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTI
- GRI
- Stock Information
- Founded
- ASTI 2005
- GRI 2018
- Country
- ASTI United States
- GRI United States
- Employees
- ASTI N/A
- GRI N/A
- Industry
- ASTI Semiconductors
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- ASTI Technology
- GRI Health Care
- Exchange
- ASTI Nasdaq
- GRI Nasdaq
- Market Cap
- ASTI 2.9M
- GRI 3.4M
- IPO Year
- ASTI N/A
- GRI N/A
- Fundamental
- Price
- ASTI $2.08
- GRI $1.65
- Analyst Decision
- ASTI
- GRI Strong Buy
- Analyst Count
- ASTI 0
- GRI 2
- Target Price
- ASTI N/A
- GRI $22.00
- AVG Volume (30 Days)
- ASTI 6.7M
- GRI 136.5K
- Earning Date
- ASTI 08-05-2025
- GRI 08-13-2025
- Dividend Yield
- ASTI N/A
- GRI N/A
- EPS Growth
- ASTI N/A
- GRI N/A
- EPS
- ASTI N/A
- GRI N/A
- Revenue
- ASTI $51,917.00
- GRI N/A
- Revenue This Year
- ASTI N/A
- GRI N/A
- Revenue Next Year
- ASTI N/A
- GRI N/A
- P/E Ratio
- ASTI N/A
- GRI N/A
- Revenue Growth
- ASTI N/A
- GRI N/A
- 52 Week Low
- ASTI $1.10
- GRI $1.10
- 52 Week High
- ASTI $11.10
- GRI $43.69
- Technical
- Relative Strength Index (RSI)
- ASTI 51.97
- GRI 57.27
- Support Level
- ASTI $2.10
- GRI $1.39
- Resistance Level
- ASTI $2.64
- GRI $1.45
- Average True Range (ATR)
- ASTI 0.49
- GRI 0.12
- MACD
- ASTI -0.00
- GRI 0.05
- Stochastic Oscillator
- ASTI 37.32
- GRI 69.79
About ASTI Ascent Solar Technologies Inc.
Ascent Solar Technologies Inc is engaged in the manufacturing, and selling of photovoltaic products (PV) solar modules that are flexible, durable, and possess attractive power-to-weight and power-to-area performance. The company is integrating its PV products into scalable and high-value markets such as agrivoltaics, aerospace, satellites, near-earth orbiting vehicles, and fixed-wing unmanned aerial vehicles (UAV). Ascent is also working to expand its portable solar chargers, such as the XD-12. The company markets and sells its products through OEMs, system integrators, distributors, retailers, and e-commerce companies.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.